- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF (STANISLASV4)

March 27, 2024 updated by: Pr. Nicolas GIRERD

Family Heritability, Investigating Gene-gene and Gene-environment Interactions in the Field of Cardiovascular Diseases - 4th VISIT (at 17 Years) of the STANISLAS COHORT

The Stanislas Cohort is a monocentric familial longitudinal cohort comprised of 1006 families (4295 subjects) from the Nancy region recruited in 1993-1995 at the Centre for Preventive Medicine (Centre de Médecine Préventive, CMP), Vandoeuvre lès Nancy for a 5-year periodic health examination, under the auspices of the Caisse Nationale d'Assurance Maladie (CNAM).

This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases, based on the study of inter-individual variability and familial segregation analysis of biological and morphological intermediate phenotypes of cardiovascular risk. The longitudinal nature of this study should enable to take into account the evolution of intermediate phenotypes related to genetic factors throughout the follow-up period. The families, consisting of two parents and at least two biological children, were deemed healthy, free of declared acute and/or chronic illness, in order to assess the effect of genetics on the variability of intermediate phenotypes studied under physiological conditions (without the influence, in the absence) of pathology.

The Stanislas Cohort is, both nationally and internationally, the only longitudinal familial cohort of supposedly healthy subjects on such a large scale.

Brief summary of ancillary study "Cardiac Functional Indices Comparison Between MRI and Echocardiography" : the ESCIF study is an ancillary study of the Stanislas cohort aiming at comparing in a cohort of supposedly healthy subjects different cardiac functional indices between two different modalities : Echocardiography and MRI. Indeed, new cardiac functional indices have been recently developed in the scope of echocardiography and would be very useful in MRI. In echography they are computed either from tissue Doppler imaging or from a specific image analysis called speckle tracking. These two techniques are accessible in MRI with the Generalized Reconstruction by Inversion of Coupled Systems (GRICS) technology which provides a motion model from which strains and strain rates may be derived and which allow longer acquisition without the constraint of breath holding (mandatory to reach high temporal resolution).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

MAIN STUDY Follow-up visit No. 4 is currently being scheduled, and is planned between 2011 and 2016.

Objectives:

  • Conduct a fourth visit, in 2011-2016, enabling a follow-up at 17 years of the cohort population.
  • Enrich the sample collection with new biobanks and clinical phenotyping of the cohort by conducting selected specific investigations and supported by specific scientific hypotheses and protocols

  • Evaluate the long-term (follow-up, monitoring) of clinical, biological, morphological data by analyzing:

    • The influence of aging (average age of parents in 1993: 45 years and in 2010-2012: 62 years).
    • The incidence and changes in prevalence of cardiovascular risk factors comprising the metabolic syndrome (MS), and their familial segregation, since as early as the second visit, in some one hundred families, at least one family member presented a MS according the definition of the NCEP-ATPIII. Approximately 20% of adults had high blood pressure (hypertension), and 50% had a body mass index above 25 kg/m2.
    • The genetic and environmental determinants, through a multifaceted approach including familial segregation and candidate genes, the progression of cardiovascular risk and the incidence of cardiovascular diseases (vascular and coronary diseases, heart failure).

Methodology, Organization:

All Cohort members will be contacted to participate in this fourth visit. The data collected will be identical to those collected during the previous visits. However, they will be enriched with new clinical phenotyping conducted at the CIC (principal investigator Prof. Zannad): collection of blood and urine samples (DNA, RNA, lymphocytic extracts, plasma biobank, urology biobank), and morphological investigations (electrocardiogram, echocardiography, carotid echotracking, arterial stiffness, systolic pressure index, abdominal aortic ultrasound). Based on previous participation rates, the recruitment of 2,000 participants (500 families) is possible.

Expected Results:

This reconvening, for the follow-up at 17 years of the Stanislas Cohort, unique in its familial nature and having already contributed in a very significant manner in terms of knowledge generated, will enable in addition to the long-term continuation of its initial objectives (gene-environment interactions and cardiovascular diseases : Sophie Visvikis-Siest) to identify more specifically the natural history of the evolution of cardiovascular risk factors, including metabolic syndrome and its components as well as the incidence and transition mechanisms toward common cardiovascular diseases, notably vascular and coronary diseases and heart failure.

ANCILLARY STUDY

Detailed description of the ESCIF ancillary study - Dr. BONNEMAINS :

Objectives :

  • to compare cardiac functional indices measured in MRI with the GRICS technique with equivalent indices measured with echocardiography.
  • to assess inter-observer reproducibility of echography and MRI.

Organization :

76 subjects from the Stanislas cohort will be included prospectively in two groups according to the echocardiographic strains and tissue Doppler velocities acquired during echocardiography : 38 subjects with normal indices, and 38 with altered indices. Each subject will be proposed an MRI examination with the GRICS technique the same day to assess the same indices.

Study design = interventional: MRI. Prospective Number of groups: 2 Enrollment: 76 Last inclusion in the ESCIF study : 23/09/2014

SUBSTUDY : PHRC I 2013 - BioSe-PreIC - Dr HUTTIN : diagnostic performance of circulating biomarkers in early screening of heart failure Design : non interventionnal study

Main objective : Determine the contribution, in addition (ontop of ) of the subject's clinical characteristics, of circulating biomarkers assays (Gal-3, PIIINP, ST2) in a general population to screen early stages of heart failure (Stage B: asymptomatic patients with structural abnormalities) validated by trans-thoracic echocardiography (diastolic function and left ventricular mass)

Inclusion crieria :

Subjects participating to the 4th visit of the STANISLAS cohort

Subjets over 40 years old

Non-inclusion criteria :

Blood sample or echocardiography unavailable

Known cardiopathy

Modarate to severe sympptoms linked to heart failure

Présence of an abnormal diastolic function (E/Ea ratio above 8) and/or left ventricular hypertrophy (left ventricular mass above 125 g/m² for men and 110 g/m² for women).

Study Type

Interventional

Enrollment (Actual)

1705

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Nancy, France, 54500
        • Centre d'Investigation Clinique -Plurithématique
      • Nancy, France, 54500
        • Centre d'Investigation Clinique- INNOVATIONS TECHNOLOGIQUES

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient having taken part in the STANISLAS troop,
  • At least 18 years old,
  • Written and signed enlightened assent,
  • Ensured social

Exclusion Criteria:

  • Patient unable to understand the informed consent,
  • patient under legal protection

STANISLAS ancillary study:

Study population = subgroup of 76 subjects from the Stanislas cohort

Eligibility:

being member of the Stanislas cohort and participating to 4th visit Specific written and signed enlightened consent for the ESCIF study

Exclusion:

contraindications for MRI examination, possibility of pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: family
each family, composed of 4 characters at least, is studied
Biological: blood and urine samples
58 ml of blood 120 ml of urine
Other Names:
  • biological analyses
  • biological collection
Genetic: blood sample
11 ml of blood
Other Names:
  • ADN and ARN collection
Other: cardiovascular assessment
echography, echodoppler, measure of blood pressure...
Other Names:
  • cardiovascular risk factors
Other: Stanislas ancillary study : MRI examination with GRICS technique

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases
Time Frame: day 1
study of inter-individual variability and familial segregation analysis of biological and morphological intermediate phenotypes of cardiovascular risk
day 1
ESCIF ancillary study : pair-wise comparison of functional indices measured in MRI and echocardiography
Time Frame: day 1
day 1

Secondary Outcome Measures

Outcome Measure
Time Frame
ESCIF ancillary study : inter-observer reproducibility of each method (MRI and Echocardiography)
Time Frame: day 1
day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pr. Nicolas GIRERD

Investigators

  • Principal Investigator: Faiez ZANNAD, PU, PH, CHU Nancy, CIC-P, INSERM

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2011

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

July 1, 2016

Study Registration Dates

First Submitted

May 12, 2011

First Submitted That Met QC Criteria

July 11, 2011

First Posted (Estimated)

July 12, 2011

Study Record Updates

Last Update Posted (Actual)

March 28, 2024

Last Update Submitted That Met QC Criteria

March 27, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2010-A01469-30

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on blood and urine samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe